mln9708

Lymphoma

Brian HillPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 65/ 100

Competitive context

243 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINBLASTINE Intensity Therapeutics, Inc.	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation	Phase 4	BBB
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB
FILGRASTIM M.D. Anderson Cancer Center	Phase 4	BB

View all 50 →

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant

BB

Indicative ·

66 / 100

AmyloidosisDormant

BB

Indicative ·

64 / 100

Higher-risk Myelodysplastic SyndromeDormant

B

Indicative ·

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.